

22 - References

References

352 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 References

1. Marcantoni WS, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 – January 2019. *J Affect Disord* 2020; 277:831–841.
2. Papakostas GI, et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. *J Clin Psychiatry* 2020; 81:19r12889.
3. Meshkat S, et al. Oral ketamine for depression: an updated systematic review. *World J Biol Psychiatry* 2023; 24:545–557.
4. Wilkinson ST, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. *Am J Psychiatry* 2018; 175:150–158.
5. Witt K, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. *Aust N Z J Psychiatry* 2020; 54:29–45.
6. Alnefeesi Y, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review and meta-analysis. *J Psychiatr Res* 2022; 151:693–709.
7. Terao I, et al. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: a systematic review and network meta-analysis. *J Affect Disord* 2024; 346:49–56.
8. Capuzzi E, et al. Long-term efficacy of intranasal esketamine in treatment-resistant major depression: a systematic review. *Int J Mol Sci* 2021; 22:9338.
9. Beck K, et al. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis. *JAMA Netw Open* 2020; 3:e204693.
10. aan het Rot M, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. *Biol Psychiatry* 2010; 67:139–145.
11. Short B, et al. Side-effects associated with ketamine use in depression: a systematic review. *Lancet Psychiatry* 2018; 5:65–78.
12. Goh KK, et al. Lamotrigine augmentation in treatment-resistant unipolar depression: a comprehensive meta-analysis of efficacy and safety. *J Psychopharmacol* 2019; 33:700–713.
13. Papadimitropoulou K, et al. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic

- review and network meta-analysis. *Curr Med Res Opin* 2017; 33:701-711.
14. Guo Q, et al. Efficacy and safety of eight enhanced therapies for treatment-resistant depression: a systematic review and network meta- analysis of RCTs. *Psychiatry Res* 2024; 339:116018.
 15. Joffe RT, et al. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. *Psychiatry Res* 1990; 32:241-251.
 16. Anderson IM. Drug treatment of depression: reflections on the evidence. *Adv Psychiatr Treat* 2003; 9:11-20.
 17. Nierenberg AA, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. *Am J Psychiatry* 2006; 163:1519-1530.
 18. Iosifescu DV, et al. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. *J Clin Psychiatry* 2005; 66:1038-1042.
 19. Abraham G, et al. T3 augmentation of SSRI resistant depression. *J Affect Disord* 2006; 91:211-215.
 20. Kelly TF, et al. Long term augmentation with T3 in refractory major depression. *J Affect Disord* 2009; 115:230-233.
 21. Parmentier T, et al. The use of triiodothyronine (T3) in the treatment of bipolar depression: a review of the literature. *J Affect Disord* 2018; 229:410-414.
 22. Nuñez NA, et al. Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. *J Affect Disord* 2022; 302:385-400.
 23. Garlow SJ, et al. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. *J Psychiatr Res* 2012; 46:1406-1413.
-

Revision #1

Created 2026-01-04 20:15:21 UTC by Omar Ayman

Updated 2026-01-04 20:15:21 UTC by Omar Ayman